KRRO - Frequency Therapeutics Inc

KRRO - Frequency Therapeutics Inc

https://www.korrobio.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire • 1 month ago • score: 0.01

- Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of ...

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

GlobeNewswire • 1 month, 3 weeks ago • score: 0.05

CAMBRIDGE, Mass., July 21, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been ...

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Korro Bio ( NASDAQ:KRRO ) , CG Oncology ( NASDAQ:CGON )

Benzinga • 4 months, 4 weeks ago • score: 0.15

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire • 5 months, 4 weeks ago • score: 0.08

CAMBRIDGE, Mass., March 18, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported full-year 2024 ...

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

GlobeNewswire • 6 months ago • score: 0.02

CAMBRIDGE, Mass., March 14, 2025 ( GLOBE NEWSWIRE ) -- Korro Bio, Inc. ( Korro ) ( Nasdaq: KRRO ) , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$98.00

52W Low

$10.29

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.60

EV/Revenue (<3 favorable)

41.37

P/S (TTM) (<3 favorable)

49.61

P/B (<3 favorable)

2.71

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.18%

Institutions (25–75% balanced)

97.13%

Shares Outstanding

9,390,900

Float

5,744,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

6,281,000

Gross Profit (TTM)

6,281,000

EPS (TTM)

-9.74

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-18.63%

ROE (TTM) (>15% strong)

-0.58%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

5.3324

Previous

5.7175

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025